Premium
Topical acne treatments in Europe and the issue of antimicrobial resistance
Author(s) -
Leccia M.T.,
Auffret N.,
Poli F.,
Claudel J.P.,
Corvec S.,
Dreno B.
Publication year - 2015
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.12989
Subject(s) - propionibacterium acnes , acne , medicine , benzoyl peroxide , azelaic acid , clindamycin , antimicrobial , dermatology , antibiotic resistance , erythromycin , antibiotics , adapalene , acne treatment , microbiology and biotechnology , chemistry , organic chemistry , biology , genetics , polymerization , polymer
Acne vulgaris (acne) is a chronic inflammatory disease of the sebaceous gland, characterized by follicular hyperkeratinization, excessive colonization by Propionibacterium acnes (P . acnes ) as well as immune reactions and inflammation. Despite an armamentarium of topical treatments available including benzoyl peroxide, retinoids and azelaic acid, topical antibiotics in monotherapies, especially erythromycin and clindamycin, are still used in Europe to treat acne. This intensive use led to antimicrobial‐resistant P. acnes and staphylococci strains becoming one of the main health issues worldwide. This is an update on the current topical acne treatments available in Europe, their mechanism of action, their potential to induce antimicrobial resistance and their clinical efficacy and safety.